Novel modalities and the regulatory pathways to clear their journey to patients are driving developments in rare disease treatments in 2025. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, gathers perspectives from three key opinion leaders across the industry about advancements in oncology and other areas, and the increasing role of patients' families in accelerating R&D.
All content for Drug Solutions is the property of Pharm Tech and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Novel modalities and the regulatory pathways to clear their journey to patients are driving developments in rare disease treatments in 2025. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, gathers perspectives from three key opinion leaders across the industry about advancements in oncology and other areas, and the increasing role of patients' families in accelerating R&D.
In this episode of the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions
Novel modalities and the regulatory pathways to clear their journey to patients are driving developments in rare disease treatments in 2025. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, gathers perspectives from three key opinion leaders across the industry about advancements in oncology and other areas, and the increasing role of patients' families in accelerating R&D.
